Vectura’s VR496, an inhaled dry powder formulation of heparin sodium, has produced positive results in a Phase 2 study in cystic fibrosis patients, says the company. The product has received orphan drug status from both the EMA and the FDA.
The study involved 77 CF patients, with 90% completing the 4-week treatment period. Patients treated with VR496 experienced reductions in induced sputum neutrophil elastase and total cell counts, as well as changes in sputum that improved airway clearance compared with placebo.
Vectura Chief Executive Chris Blackwell welcomed the results, stating that, “This study confirms the potential therapeutic benefit of VR496 in a variety of airway disorders and justifies further clinical evaluation. These data will be of value in our on-going discussions with prospective licensing partners.”
Read the company’s press release.
